AA- Turkey will launch its coronavirus vaccine between June and August this year, announced this Monday Nadir Kocak, leader of the country’s vaccine development project.
Leading Turkish universities and laboratories, including Ankara-based Middle East Technical University and Istanbul-based Acibadem Labmed clinical laboratory, are conducting trials for messenger RNA vaccine (MRNA) against COVID-19.
In an interview with Anadolu Agency, Kocak said that mRNA is known to the world as a third-generation vaccination technology.
“One of our biggest goals was to bring this technology to our country,” he said, adding that they began working on the vaccine almost eight months after BioNTech / Pfizer and Moderna, pharmaceutical companies that have already launched their respective vaccines.
“Although this seems like a disadvantage, starting late has given us the opportunity to follow the latest publications in the world on the stability of the virus protein. We have seen formulas that use organizations that have advanced in the matter. We have moved towards the development of a more stable and effective vaccine, “he added.
He noted that they are working on a vaccine that could be kept for up to six months at room temperature, which would eliminate the need for the cold chain.
Kocak said they developed their first vaccine for MRNA a month and a half ago, and now they are heading towards the final stage of animal testing.
He added that the experts developed three different vaccine formulas and have completed the synthesis of each.
“We will begin human trials within two months with the most effective one. Our goal is to create an effective and temperature-resistant vaccine. Our goal is to offer this vaccine at the service of humanity in the summer months,” he added.
Noting that the study stages were kept short due to the pandemic, Kocak said all the vaccines received approval for emergency use in their third phase.
For now, two doses of the vaccine will be given two weeks apart, he said, adding that this ratio could change in the next two to three years.